Argus Research Maintains Buy on CVS Health, Raises Price Target to $114
Argus Research analyst Steve Silver maintains CVS Health (NYSE:CVS) with a Buy and raises the price target from $104 to $114.
Read original at benzingaStocks · News reference
Losing a health plan is stressful at any age. Losing it in retirement, when a familiar doctor and a specific drug list are woven into daily life, is worse. Yet that is exactly what happened to a large group of older
Reference details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Argus Research analyst Steve Silver maintains CVS Health (NYSE:CVS) with a Buy and raises the price target from $104 to $114.
Read original at benzingaCostco plans a limited Medicare rollout with SCAN Group as insurers face rising costs and regulatory scrutiny.
Read original at benzingaFiled: 2026-08-17 AccNo: 0001193125-26-354096 Size: 159 KB Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits
Read original at edgarViking Global Investors' second-quarter 13F shows new stakes in SPCX, MS, QCOM, CVS and exits in CRWV and GOOGL.
Read original at benzingaLaunched July 1, this partnership builds on the organizations' long-standing collaboration in end stage kidney disease and expands earlier into the disease journey, when intervention can have the greatest impact.As
Read original at benzingaMark Cuban is urging funds to divest from major health insurers. Here’s how broad-market ETFs remain exposed to the companies he’s targeting.
Read original at benzinga